Literature DB >> 8458164

Erythropoietin therapy for anemia of prematurity.

P G Gallagher1, R A Ehrenkranz.   

Abstract

Recombinant human erythropoietin administration may prove to be a valuable adjunct in the treatment of the anemia of prematurity. This report provides an overview of fetal and neonatal erythropoiesis, the biology of erythropoietin, and the pathophysiology of the anemia of prematurity. The clinical trials using recombinant human erythropoietin in the treatment of anemia of prematurity are reviewed. Important considerations of this therapy are discussed.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8458164

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN： 0095-5108            Impact factor:   3.430


  7 in total

1.  Erythropoietin concentrations and erythropoiesis in newborns suffering from renal agenesis and congenital kidney diseases.

Authors:  H Fahnenstich; C Dame
Journal:  Eur J Pediatr       Date:  1996-03       Impact factor: 3.183

Review 2.  Anaemia of prematurity. Epidemiology, management and costs.

Authors:  M P Meyer
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

3.  Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants.

Authors:  V P Carnielli; R Da Riol; G Montini
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-07       Impact factor: 5.747

4.  Recombinant haemopoietic growth factors in the newborn--will they be useful?

Authors:  C A Wardrop; B M Holland
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

Review 5.  Anemia in the preterm infant: erythropoietin versus erythrocyte transfusion--it's not that simple.

Authors:  Isabelle Von Kohorn; Richard A Ehrenkranz
Journal:  Clin Perinatol       Date:  2009-03       Impact factor: 3.430

6.  Iron absorption and oxidant stress during erythropoietin therapy in very low birth weight premature infants: a cohort study.

Authors:  James K Friel; Khalid Aziz; Wayne L Andrews; Robert E Serfass
Journal:  BMC Pediatr       Date:  2005-08-05       Impact factor: 2.125

7.  Erythropoiesis suppression is associated with anthrax lethal toxin-mediated pathogenic progression.

Authors:  Hsin-Hou Chang; Tsung-Pao Wang; Po-Kong Chen; Yo-Yin Lin; Chih-Hsien Liao; Ting-Kai Lin; Ya-Wen Chiang; Wen-Bin Lin; Chih-Yu Chiang; Jyh-Hwa Kau; Hsin-Hsien Huang; Hui-Ling Hsu; Chi-Yuan Liao; Der-Shan Sun
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.